Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment.

Drugs R D · 2018 · PMC5995786 · PMID 29488154

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

On the contrary, a decreasing trend in fasiglifam exposure was observed with progressive hepatic impairment, while exposure to the inactive metabolite M-I increased.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.